, /PRNewswire/ -- 集体诉讼律师 Juan Monteverde 与 Monteverde &amp; Associates PC（“M&amp;A 集体诉讼事务所”）为股东追回了数百万美元，并在 2025 年 ISS 证券集体诉讼服务报告中被评为 前 50 名事务所。我们总部位于 帝国大厦，位于纽约市，并正在调查
<ul>
<li>Kezar Life Sciences, Inc. (NASDAQ: KZR) 与其出售给 Aurinia Pharmaceuticals Inc.相关。根据拟议交易的条款，Kezar 股东预计将获得每股 6.955 美元现金和一项不可转让的或有价值权利。</li>
</ul>
点击此处获取更多信息 https://monteverdelaw.com/case/kezar-life-sciences-inc/ 。 这是免费的，您无需支付任何费用或承担任何义务。
<ul>
<li>Centessa Pharmaceuticals plc (NASDAQ: CNTA) 与其出售给 Eli Lilly and Company 相关。根据拟议交易的条款，Centessa 股东预计将获得每股 38.00 美元现金和一项不可转让的或有价值权利，持有人有权在达到某些里程碑的情况下获得最多 9.00 美元的总额。</li>
</ul>
点击此处获取更多信息 https://monteverdelaw.com/case/centessa-pharmaceuticals-plc/ 。 这是免费的，您无需支付任何费用或承担任何义务。
<ul>
<li>Affinity Bancshares, Inc. (NASDAQ: AFBI) 与其出售给 Fidelity Bancshares (N.C.), Inc.相关。根据拟议交易的条款，Affinity 股东预计将获得每股 23.00 美元现金。</li>
</ul>
点击此处获取更多信息 https://monteverdelaw.com/case/affinity-bancshares-inc-2/ 。 这是免费的，您无需支付任何费用或承担任何义务。
<ul>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 与其出售给 Biogen, Inc.相关。根据拟议交易的条款，Apellis 股东预计将获得每股 41.00 美元现金和一项不可转让的或有价值权利，允许在满足某些年度全球净销售阈值的情况下获得每股两次 2.00 美元的付款。</li>
</ul>
点击此处获取更多信息 https://monteverdelaw.com/case/apellis-pharmaceuticals-inc/ 。 这是免费的，您无需支付任何费用或承担任何义务。
并非所有律师事务所都是一样的。 在您聘请律师事务所之前，您应该与律师交谈并询问：
<ol>
<li>您是否提起集体诉讼并出庭？</li>
<li>您上次为股东追回资金是什么时候？</li>
<li>您在哪些案件中追回了资金，金额是多少？</li>
</ol>
关于 Monteverde &amp; Associates PC
我们的事务所进行诉讼并为股东追回资金……我们在帝国大厦的办公室进行此项工作。我们是一家全国性的集体诉讼证券事务所，在审判和上诉法院，包括美国最高法院，拥有成功的业绩。
没有公司、董事或高管高于法律。 如果您拥有上述公司普通股并有疑虑或希望免费获取更多信息，请访问我们的 网站 或通过电子邮件联系 Juan Monteverde, Esq.，电子邮件地址为 [email protected]，或拨打电话 (212) 971-1341。
联系方式：
Juan Monteverde, Esq.
MONTEVERDE &amp; ASSOCIATES PC
帝国大厦 350 Fifth Ave. Suite 4740
纽约，NY 10118
美国
[email protected]
电话：(212) 971-1341
律师广告。(C) 2026 Monteverde &amp; Associates PC。本广告的责任律师事务所为 Monteverde &amp; Associates PC (www.monteverdelaw.com)。之前的结果并不保证未来事务的类似结果。
来源 Monteverde &amp; Associates PC
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA4Jk5ld3NJdGVtSWQ9REMyOTcyMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDgxNDE1UFJfTkVXU19VU1BSX19fX19EQzI5NzIz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA4Jk5ld3NJdGVtSWQ9REMyOTcyMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDgxNDE1UFJfTkVXU19VU1BSX19fX19EQzI5NzIz"/>

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

CNTA

集体诉讼律师 Juan Monteverde 正在调查涉及 Kezar Life Sciences（KZR）、Centessa Pharmaceuticals（CNTA）、Affinity Bancshares（AFBI）和 Apellis Pharmaceuticals（APLS）的合并。KZR 的股东预计将获得每股 6.955 美元，CNTA 每股 38.00 美元，AFBI 每股 23.00 美元，以及 APLS 每股 41.00 美元，某些情况下还包括附带价值权。该公司在为股东追回资金方面有着成功的记录，并为对这些交易感到担忧的人提供免费的咨询服务

, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde &amp; Associates PC (the &#34;M&amp;A Class Action Firm&#34;), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
<div class="lb-trans">, /PRNewswire/ -- 集体诉讼律师 Juan Monteverde 与 Monteverde &amp; Associates PC（“M&amp;A 集体诉讼事务所”）为股东追回了数百万美元，并在 2025 年 ISS 证券集体诉讼服务报告中被评为 前 50 名事务所。我们总部位于 帝国大厦，位于纽约市，并正在调查
</div><ul>
<li>Kezar Life Sciences, Inc. (NASDAQ: KZR) related to its sale to Aurinia Pharmaceuticals Inc. Under the terms of the proposed transaction, Kezar shareholders are expected to receive $6.955 per share in cash and one non-transferable contingent value right.</li>
</ul>
<div class="lb-trans"><ul>
<li>Kezar Life Sciences, Inc. (NASDAQ: KZR) 与其出售给 Aurinia Pharmaceuticals Inc.相关。根据拟议交易的条款，Kezar 股东预计将获得每股 6.955 美元现金和一项不可转让的或有价值权利。</li>
</ul>
</div>Click here for more information https://monteverdelaw.com/case/kezar-life-sciences-inc/ . It is free and there is no cost or obligation to you.
<div class="lb-trans">点击此处获取更多信息 https://monteverdelaw.com/case/kezar-life-sciences-inc/ 。 这是免费的，您无需支付任何费用或承担任何义务。
</div><ul>
<li>Centessa Pharmaceuticals plc (NASDAQ: CNTA) related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, Centessa shareholders are expected to receive $38.00 per share in cash and one non-transferable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones.</li>
</ul>
<div class="lb-trans"><ul>
<li>Centessa Pharmaceuticals plc (NASDAQ: CNTA) 与其出售给 Eli Lilly and Company 相关。根据拟议交易的条款，Centessa 股东预计将获得每股 38.00 美元现金和一项不可转让的或有价值权利，持有人有权在达到某些里程碑的情况下获得最多 9.00 美元的总额。</li>
</ul>
</div>Click here for more information https://monteverdelaw.com/case/centessa-pharmaceuticals-plc/ . It is free and there is no cost or obligation to you.
<div class="lb-trans">点击此处获取更多信息 https://monteverdelaw.com/case/centessa-pharmaceuticals-plc/ 。 这是免费的，您无需支付任何费用或承担任何义务。
</div><ul>
<li>Affinity Bancshares, Inc. (NASDAQ: AFBI) related to its sale to Fidelity Bancshares (N.C.), Inc. Under the terms of the proposed transaction, Affinity shareholders are expected to receive $23.00 per share in cash.</li>
</ul>
<div class="lb-trans"><ul>
<li>Affinity Bancshares, Inc. (NASDAQ: AFBI) 与其出售给 Fidelity Bancshares (N.C.), Inc.相关。根据拟议交易的条款，Affinity 股东预计将获得每股 23.00 美元现金。</li>
</ul>
</div>Click here for more information https://monteverdelaw.com/case/affinity-bancshares-inc-2/ . It is free and there is no cost or obligation to you.
<div class="lb-trans">点击此处获取更多信息 https://monteverdelaw.com/case/affinity-bancshares-inc-2/ 。 这是免费的，您无需支付任何费用或承担任何义务。
</div><ul>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) related to its sale to Biogen, Inc. Under the terms of the proposed transaction, Apellis shareholders are expected to receive $41.00 per share in cash and a non-transferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE.</li>
</ul>
<div class="lb-trans"><ul>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 与其出售给 Biogen, Inc.相关。根据拟议交易的条款，Apellis 股东预计将获得每股 41.00 美元现金和一项不可转让的或有价值权利，允许在满足某些年度全球净销售阈值的情况下获得每股两次 2.00 美元的付款。</li>
</ul>
</div>Click here for more info https://monteverdelaw.com/case/apellis-pharmaceuticals-inc/ . It is free and there is no cost or obligation to you.
<div class="lb-trans">点击此处获取更多信息 https://monteverdelaw.com/case/apellis-pharmaceuticals-inc/ 。 这是免费的，您无需支付任何费用或承担任何义务。
</div>NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:
<div class="lb-trans">并非所有律师事务所都是一样的。 在您聘请律师事务所之前，您应该与律师交谈并询问：
</div><ol>
<li>Do you file class actions and go to Court?</li>
<li>When was the last time you recovered money for shareholders?</li>
<li>What cases did you recover money in and how much?</li>
</ol>
<div class="lb-trans"><ol>
<li>您是否提起集体诉讼并出庭？</li>
<li>您上次为股东追回资金是什么时候？</li>
<li>您在哪些案件中追回了资金，金额是多少？</li>
</ol>
</div>About Monteverde &amp; Associates PC
<div class="lb-trans">关于 Monteverde &amp; Associates PC
</div>Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
<div class="lb-trans">我们的事务所进行诉讼并为股东追回资金……我们在帝国大厦的办公室进行此项工作。我们是一家全国性的集体诉讼证券事务所，在审判和上诉法院，包括美国最高法院，拥有成功的业绩。
</div>No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.
<div class="lb-trans">没有公司、董事或高管高于法律。 如果您拥有上述公司普通股并有疑虑或希望免费获取更多信息，请访问我们的 网站 或通过电子邮件联系 Juan Monteverde, Esq.，电子邮件地址为 [email protected]，或拨打电话 (212) 971-1341。
</div>Contact:
<div class="lb-trans">联系方式：
</div>Juan Monteverde, Esq.
<div class="lb-trans">Juan Monteverde, Esq.
</div>MONTEVERDE &amp; ASSOCIATES PC
<div class="lb-trans">MONTEVERDE &amp; ASSOCIATES PC
</div>The Empire State Building 350 Fifth Ave. Suite 4740
<div class="lb-trans">帝国大厦 350 Fifth Ave. Suite 4740
</div>New York, NY 10118
<div class="lb-trans">纽约，NY 10118
</div>United States of America
<div class="lb-trans">美国
</div>[email protected]
<div class="lb-trans">[email protected]
</div>Tel: (212) 971-1341
<div class="lb-trans">电话：(212) 971-1341
</div>Attorney Advertising. (C) 2026 Monteverde &amp; Associates PC. The law firm responsible for this advertisement is Monteverde &amp; Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
<div class="lb-trans">律师广告。(C) 2026 Monteverde &amp; Associates PC。本广告的责任律师事务所为 Monteverde &amp; Associates PC (www.monteverdelaw.com)。之前的结果并不保证未来事务的类似结果。
</div>SOURCE Monteverde &amp; Associates PC
<div class="lb-trans">来源 Monteverde &amp; Associates PC
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA4Jk5ld3NJdGVtSWQ9REMyOTcyMyZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDgxNDE1UFJfTkVXU19VU1BSX19fX19EQzI5NzIz" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC29723&amp;Transmission_Id=202604081415PR_NEWS_USPR_____DC29723&amp;DateId=20260408"/>

14:15 ETSHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS

prnewswire

Centessa Pharmaceuticals

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

Affinity Bancshares

标普全球医疗股指数 ETF - iShares

Apellis Pharma

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

医疗业 ETF - SPDR

Kezar Life Sciences

生物科技 ETF - VanEck Vectors

Invesco Nasdaq Biotechnology ETF

14:15 股东警示：并购集体诉讼公司正在调查合并——Kezar Life Sciences、Centessa Pharmaceuticals、Affinity Bancshares 和 Apellis Pharma